CBD and menopause: current knowledge, studies, and advice for women's well-being
The transition to menopause â whether perimenopause or postmenopause â is a major biological milestone in a woman's life. Marked by natural hormonal variations, this period is sometimes accompanied by a search for daily comfort, relaxation, and rebalancing of one's lifestyle.
Given these wellness challenges, interest in cannabidiol (CBD) and hemp extracts has grown considerably. However, between international usage trends, qualitative studies, and the strict legal framework in France and Europe, it is essential to have clear and rigorous information. What is the legal status of CBD products? What does research say, and how can one navigate this period with peace of mind? Here is a comprehensive overview.
What is CBD and what is its link to the human body?
Cannabidiol, a plant compound from hemp
CBD (cannabidiol) is one of many phyto-cannabinoid compounds naturally synthesized by hemp (Cannabis sativa L.). Unlike THC (tetrahydrocannabinol), CBD has no psychotropic effect, does not alter consciousness, and does not cause addiction.
In France and the European Union, hemp-derived products must strictly contain a THC level of less than 0.3% to ensure the total absence of narcotic effects.
The endocannabinoid system and homeostasis
The human body houses a physiological network called the endocannabinoid system (ECS). Present in nerve tissues, the immune system, and the skin, the ECS helps maintain homeostasis, which is the body's general balance.
During menopause, fluctuations in estrogen can alter the body's natural response to environmental stressors. It is this indirect interaction between cannabinoids and ECS receptors that has piqued the interest of researchers in the field of wellness and relaxation.
What do international research studies say?
Several academic surveys and medical guidelines published in recent years provide insight into the perception and use of hemp by women in midlife.
| Organization / Study | Sample & Methodology | Key findings and observations |
|---|---|---|
| Guidelines from the SOGC (Society of Obstetricians and Gynaecologists of Canada) | Review of scientific literature | Observation of a lack of conclusive clinical trials; recommendation for open and non-stigmatizing dialogue between patients and healthcare providers. |
| MIND Program - McLean Hospital / Harvard (Dr. Staci Gruber) | Observational survey of 258 women | Nearly 80% of respondents report using hemp to support their search for relaxation, nighttime comfort, or emotional balance. |
| University of Alberta (Canada) | Qualitative study via semi-structured interviews | Highlighted a growing need for reliable information and a lack of clear regulatory benchmarks for consumers. |
Key takeaways
- Interest focused on relaxation: Field surveys (notably those conducted at Harvard Medical School) show that users primarily seek support for their evening routine or during periods of temporary stress.
- Difference between perimenopause and postmenopause: Women in perimenopause report more frequent mood swings and express a greater need for support than postmenopausal women.
- Absence of medical claims: International bodies, such as the North American Menopause Society (NAMS), point out that in the absence of controlled clinical trials, CBD cannot be classified as a medical treatment nor presented as a remedy for the manifestations of menopause.
The European regulatory framework: The Novel Food regulation
It is crucial to understand the regulations governing the distribution of CBD products in Europe to make informed and compliant choices.
The status of ingestible products (Oils and Foodstuffs)
Under the European Regulation on Novel Foods (Novel Food - EU Regulation 2015/2283), any ingredient that was not consumed to a significant degree in the European Union before May 15, 1997, is considered a Novel Food.
- Scope: This framework applies to all ingested cannabinoids, including sublingual oils (whether Full Spectrum, Broad Spectrum, or isolate-based), as well as capsules, gummies, and enriched infusions.
- Current legal situation: To date, the European Food Safety Authority (EFSA) is reviewing scientific dossiers submitted by manufacturers, but no definitive market authorization as a food supplement or foodstuff has been issued yet. Consequently, the marketing of CBD oils intended for human consumption remains strictly regulated and not approved as food in Europe.
Regulatorily recognized uses
To fit within a compliant legal framework, CBD-based products are primarily marketed as:
- Cosmetic products: CBD balms, skin application oils, and creams are governed by the European Cosmetics Regulation (EC No. 1223/2009). They provide comfort, soothing, and hydration to the skin.
- Vaping products: Intended exclusively for inhalation via suitable electronic devices.
Usage predictions, medical dialogue, and precautions
Before integrating CBD products into one's wellness routine during menopause, several rules of caution must be followed:
Regulatory warnings and usage precautions:
- Not a medication: CBD should never replace a medical prescription or hormone replacement therapy (HRT) for menopause.
- Prior medical advice: If you are undergoing medical treatment, you must consult your doctor or gynecologist. CBD is metabolized by the liver and may interfere with the action of certain medications.
- Age and health restrictions: CBD products are strictly prohibited for minors under 18 and are not recommended for pregnant or breastfeeding women.
In summary
CBD draws legitimate interest from women wishing to promote their well-being and serenity during menopause. However, the lack of approved food supplement status in Europe (Novel Food) and the strict prohibition of therapeutic claims necessitate a cautious approach.
Prioritizing certified cosmetics, informing oneself about the quality of the hemp, and communicating transparently with a healthcare professional remain the best practices for approaching this transition with peace of mind.
